Health and economic benefits of an accelerated program of research to combat global infectious diseases

CMAJ. Canadian Medical Association Journal

Volumn 171, Issue 10, 2004, Pages 1203-1208

  Jha, Prabhat ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; CANADA; CAUSE OF DEATH; COST OF ILLNESS; HUMAN; INFECTION CONTROL; INFECTION RATE; MEDICAL RESEARCH; MORTALITY; POLICY; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 8744317805     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1041634     Document Type: Review

References (46)

1. Jha P, Mills A, Hanson K, Kumaranayake L, Conteh L, Kurowski C, et al. Improving the health of the global poor. Science 2002;295(5562):2036-9.
2. World Health Organization. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: The Organization; 2002.
3. Jha P, Mills A. Improving health outcomes of the poor. Report of Working Group 5 of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2002.
4. Naylor D, Basrur S, Bergeron MG, Brunham RC, Butler-Jones D, Dafoe G, et al; National Advisory Committee on SARS and Public Health. Learning from SARS: renewal of public health in Canada. Ottawa: Health Canada; 2003. Available: www.hc-sc.gc.ca/english/pdf/sars/sars-e.pdf (accessed 2004 Oct 13).
5. United Nations. Population division, revision of the world population estimates and projections. New York: UN; 1998.
6. Ahmad OB, Lopez AD, Inoue M. The decline in child mortality: a reappraisal. Bull World Health Organ 2000;78(10):1175-91.
7. World Health Organization. Investing in health research and development. Report of the Ad Hoc Committee on Health Research Relating to Future Intervention Options. Geneva: The Organization; 1996.
8. Weatherall D, Greenwood B, Chee HL, Wasi P. Science and technology for disease control: past, present, and future. In: Jamison DT, Alleyne GA, Breman JG, Claeson M, Jha P, et al, editors. Disease control priorities in developing countries. New York: Oxford University Press. In press.
9. Easterlin RA. How beneficent is the market? A look at the modern history of mortality. Eur Rev Econ Hist 1999;3:257-94.
10. Jamison D, Sachs JD. The economic benefits of disease control. In: Jamison DT, Alleyne GA, Breman JG, Claeson M, Jha P, et al. Disease control priorities in developing countries. New York: Oxford University Press. In press.
11. US Centers for Disease Control. Ten great public health achievements - United States, 1900-1999. MMWR 1999;48(50):241-3. Available: www.cdc.gov/mmwr/PDF/wk/mm4812.pdf (accessed 2004 Oct 19).
12. England S, Loevinsohn B, Melgaard B, Kou U, Jha P. The evidence base for interventions to reduce mortality from vaccine-preventable diseases in low and middle-income countries [CMH working paper no WG5:10]. Commission on Macroeconomics and Health (CMH); 2001. Available: www.cmhealth .org/docs/wg5_paper10.pdf (accessed 2004 Oct 13).
13. Dye C. Tuberculosis 2000-2010: control, but not elimination. Int J Tuberc Lung Dis 2000;(Suppl 4):S146-52.
14. Peto R, Baigent C. Trials: the next 50 years. Large scale randomised evidence of moderate benefits. BMJ 1998;317:1170-1.
15. Nagelkerke NJ, Jha P, de Vlas SJ, Korenromp EL, Moses S, Blanchard JF, et al. Modelling HIV/AIDS epidemics in Botswana and India: impact of interventions to prevent transmission. Bull World Health Organ 2002;80(2):89-96.
16. Daar AS, Thorsteinsdottir H, Martin DK, Smith AC, Nast S, Singer PA. Top ten biotechnologies for improving health in developing countries. Nat Genet 2002;32(2):229-32.
17. World Health Organization. Genomics and global health: report of the Advisory Committee on Health Research. Geneva: The Organization; 2002. Available: www .who.int/whosis/genomics/pdf/genomics_report.pdf (accessed 2004 Oct 13).
18. Land KM. The mosquito genome: perspectives and possibilities. Trends Parasitol 2003;19:103-5.
19. Weatherall DJ, Clegg JB. Genetic variability in response to infection: malaria and after. Genes Immun 2002;3:331-7.
20. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, et al. The Genome sequence of the SARS-associated coronavirus. Science 2003;300(5624):1399-404.
21. Jha P, Nagelkerke JD, Ngugi EN, Prasada Rao JV, Willbond B, Moses S, et al. Reducing HIV transmission in developing countries. Science 2001;292:224-5.
22. Nelson KE, Celentano DD, Eiumtrakol S, Hoover DR, Beyrer C, Suprasert S, et al. Changes in sexual behavior and a decline in HIV infection among young men in Thailand. N Engl J Med 1996;335(5):297-303.
23. Johnston R. Microbicides 2002: an update. AIDS Patient Care STDS 2002;16 (9):419-30.
24. Webby RJ, Webster RG. Are we ready for pandemic influenza? Science 2003;302:1519-22.
25. Laxminarayan R et al. Drug resistance. In: Jamison DT, Alleyne GA, Breman JG, Claeson M, Jha P, et al. Disease control priorities in developing countries. New York: Oxford University Press. In press.
26. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science 1998;280:1871-3.
27. Hira SK, Panchal K, Parmar PA, Bhatia VP. High resistance to antiretroviral drugs: the Indian experience. Int J STD AIDS 2004;15(3):173-7.
28. De Vlas SJ, Nagelkerke NJ, Jha P, Plummer FA. Mother-to-child HIV transmission and ARVs. Science 2002 13;298(5601):2129.
29. Breman JG, Alilio MS, Mills A. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg 2004;71 (2 Suppl):1-15.
30. Jamison DT, Sachs JD, Wang J. The effect of the AIDS epidemic on economic welfare in sub-Saharan Africa [CMH working paper no WG1:13]. Commission on Macroeconomics and Health (CMH); 2001.
31. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva: World Health Organization; 1998.
32. Bloom DE, Mahal A, Rosenberg L, Sevilla S, Steven D, Weston M. Asia's economies and the challenge of AIDS. Manila: Asian Development Bank; 2004.
33. Copenhagen Consensus 2004. The top 10 challenges. Available: www.copenhagen consensus.com/Defaultasp?ID=164 (accessed 2004 Oct 13).
34. Kumar R. Plague outbreak in 2001 in northern India. To be presented at Controlling the risk: science to combat global infectious diseases; Toronto; Nov 9-10, 2004.
35. World Health Organization. Global Forum for Health Research: the 10/90 report on health research 2001-2002. Geneva; The Organization: 2003.
36. Murphy KM, Topel RH, editors. The economic value of medical research. In: Measuring the gains of medical reseaerch: an economic approach. Chicago: University of Chicago; 2002. p. 41-73.
37. Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, Berkley S, et al. Medicine. The need for a global HIV vaccine enterprise. Science 2003;300:2036-9.
38. Varmus H, Klausner R, Zerhouni E, Acharya T, Daar AS, Singer PA. Public health. Grand challenges in global health. Science 2003;302:398-9.
39. Singh B. Innovations and challenges in funding rapid research responses to emerging infectious diseases: lessons learned from the outbreak of severe acute respiratory syndrome. Can J Infect Dis Med Microbiol 2004;15(3):167-70.
40. Maskalyk J. Medical journals and global medicine [editorial]. CMAJ 2004;170 (1):65.
41. Cutler DM, Kadiyala S. The return to biomedical research: treatment and behavioral effects. In: Murphy KM, Topel RH, editors. Measuring the gains of medical research: an economic approach. Chicago: University of Chicago; 2002. p. 110-62.
42. Trends in developmental assistance. Organization for Economic Co-operation and Development (OECD); 2003. Available: www.oecd.org/dataoecd/42/ 21 /1860310.gif (accessed 2004 Oct 14).
43. Labbe AC, Patel S, Crandall I, Kain KC. A molecular surveillance system for global patterns of drug resistance in imported malaria. Emerg Infect Dis 2003;9 (1):33-6.
44. Fowke KR, Kaul R, Rosenthal KL, Oyugi J, Kimani J, Rutherford WJ, et al. HIV-1-specific cellular immune responses among HIV-1-resistant sex workers. Immunol Cell Biol 2000;78(6):586-95.
45. Carter R, Mendis KN. Evolutionary and historical aspects of the burden of malaria. Clin Microbiol Rev 2002;15(4):564-94.
46. Mathers CD, Lopez A, Stein C, Ma Fat D, Rao C, Inoue M, et al. Deaths and disease burden by cause: global burden of disease estimates for 2001 by World Bank country groups. Washington (DC): World Bank; 2003. Available: www.fic.nih .gov/dcpp/wps/wp18.pdf (accessed 2004 Oct 19).